Tower Research Capital LLC (Trc) Aveo Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$8.48 - $14.97 $50,574 - $89,281	5,964 Added 217.74%	8,703 $130,000
Q3 2022 Nov 10, 2022	BUY	$6.61 - $8.72 $13,920 - $18,364	2,106 Added 332.7%	2,739 $23,000
Q2 2022 Aug 15, 2022	SELL	$3.51 - $6.67 $2,853 - $5,422	-813 Reduced 56.22%	633 $4,000
Q1 2022 May 12, 2022	SELL	$3.15 - $6.01 $37,954 - $72,414	-12,049 Reduced 89.28%	1,446 $8,000
Q4 2021 Feb 14, 2022	BUY	$4.69 - $7.4 $48,588 - $76,664	10,360 Added 330.46%	13,495 $63,000
Q3 2021 Nov 15, 2021	SELL	$5.12 - $6.89 $131,220 - $176,583	-25,629 Reduced 89.1%	3,135 $20,000
Q2 2021 Aug 16, 2021	BUY	$6.21 - $7.45 $140,650 - $168,735	22,649 Added 370.38%	28,764 $190,000
Q1 2021 May 17, 2021	BUY	$5.97 - $15.28 $8,966 - $22,950	1,502 Added 32.56%	6,115 $45,000
Q4 2020 Feb 16, 2021	SELL	$5.08 - $6.68 $51,719 - $68,009	-10,181 Reduced 68.82%	4,613 $27,000
Q3 2020 Nov 16, 2020	BUY	$4.16 - $6.26 $51,654 - $77,730	12,417 Added 522.38%	14,794 $88,000
Q2 2020 Aug 13, 2020	BUY	$3.47 - $9.99 $8,241 - $23,726	2,375 Added 118750.0%	2,377 $12,000
Q1 2020 May 15, 2020	BUY	$2.6 - $6.9 $5 - $13	2 New	2 $0

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.